0H22 Stock Chart & Stats
kr23.55
kr0.10(0.43%)
At close: 4:00 PM EDT
kr23.55
kr0.10(0.43%)
Day’s Range― - ―
52-Week Rangekr19.46 - kr34.80
Previous CloseN/A
Volume189.00
Average Volume (3M)1.13K
Market Cap
kr1.55B
Enterprise Valuekr1.31K
Total Cash (Recent Filing)kr340.82M
Total Debt (Recent Filing)kr21.47M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Oct 29, 2026EPS Estimate
-1.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.55
Shares Outstanding65,804,360
10 Day Avg. Volume645
30 Day Avg. Volume1,134
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.13
Revenue Forecast (FY)kr166.80M
Bulls Say, Bears Say
Bulls Say
Proprietary Antibody Discovery PlatformsProprietary discovery and validation capabilities can support repeatable generation of differentiated oncology candidates, creating a durable foundation for internal development and potential collaboration or licensing revenue.
Very Low Financial LeverageMinimal debt reduces refinancing and solvency risk and preserves financial flexibility relative to highly leveraged peers, although the company still faces funding needs because operating losses continue.
High Gross Margin ProfileThe very high gross margin indicates limited direct cost intensity in the reported revenue base and suggests that successful partnerships or future product commercialization could carry attractive incremental economics.
Bears Say
Severe Revenue ContractionSuch a steep decline signals instability in collaboration, licensing, or milestone revenue and makes planning difficult. Sustained revenue weakness could delay pipeline investment and increase dependence on new agreements.
Persistent Cash ConsumptionHeavy recurring cash burn means BioInvent must reduce spending, increase revenue, or obtain external capital to fund development. Continued dependence on financing can raise dilution risk and constrain strategic flexibility.
Deep Structural Operating LossesDeep losses and negative returns on equity show that the current operating model is not yet economically self-sustaining. Without successful clinical progress or partnerships, shareholder value may remain pressured by ongoing losses and funding needs.
BioInvent International AB News
0H22 FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest share price was kr19.46 and its highest was kr34.80 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is kr1.55B.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Oct 29, 2026 which is in 59 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Aug 27, 2026. The company reported -kr1.899 earnings per share for the quarter.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Overvalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate is -1.98.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -kr1.899 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in GB:0H22
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioInvent International AB
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
Technical Analysis
Alligator Bioscience AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―